跳至主要内容
临床试验/NCT03990909
NCT03990909招募中不适用

A Pilot Study of Dietary Supplementation With Branched Chain Amino Acids on Sleep

Portland VA Medical Center2 个研究点 分布在 1 个国家目标入组 300 人开始时间: 2019年3月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
300
试验地点
2
主要终点
Recruitment and retention rates

研究概览

简要总结

Individuals will be recruited from the VA Portland Health Care System and the community affiliated with Oregon Health & Science University. Traumatic brain injury status will be assessed as a contributing factor. Subjects will be randomized to one of 3 groups (BCAA or one of 2 placebo conditions) and instructed to consume study product twice daily for 21 days. Self-report questionnaires, wrist actigraphy, pressure pain testing, and cognitive function will be assessed pre and post the experimental period.

详细描述

The goal of this proposal is to explore the feasibility of, and potential for, dietary supplementation with branched chain amino acids (BCAAs) to effect sleep quality and cognitive function in Veterans. The BCAAs (Leucine, Isoleucine, and Valine) cannot be synthesized endogenously (i.e., they must be obtained through the diet) and are the precursors to >50% of de novo glutamate and GABA synthesis in the brain, which are the primary excitatory and inhibitory neurotransmitters, respectively. Preclinical evidence strongly suggests that dietary BCAA supplementation restores normal sleep-wake patterns and cognitive function following TBI through a restoration in the global cortical excitation:inhibition ratio. BCAA supplementation has been studied extensively in healthy humans and in a variety of disease states, including following TBI, but not yet in Veterans in the chronic phase of recovery from TBI. BCAAs are a commercially available dietary supplement and very well tolerated with minimal side-effects.

Subjects will be randomized in a double-blind fashion through the VA Research Pharmacy to one of three groups: 1) BCAA; 60 g/day in two 30 g doses, 2) rice protein; 60 g/day in two 30 g doses, and 3) placebo; 60 g microcrystalline cellulose in two 30 g doses. BCAA and placebo will be prepared by the VA Research Pharmacy and dispensed in a blinded fashion to Veterans after demonstrating informed consent. Following a ~4-week period of baseline, Veterans will be instructed to consume study product after waking and ~6 hours later, on an empty stomach for a period of up to 21-days. Self-report questionnaires assessing sleep quality, cognitive function, trauma-related symptom severity, and other measures of mental and physical well-being will be administered before and after the experimental period. Wrist actigraphy will be continuously collected over the baseline and the experimental period. Cognitive function will be assessed before and after the experimental period using an established battery of neuropsychological tests (i.e., selected tests from WAIS, D-KEFS, HVLT, COWAT, among others. Pressure pain testing will be conducted before and after the experimental period.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 89 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • English Speaking
  • Accessible via phone
  • Sleep problems

排除标准

  • Decisional impairment
  • Nickel allergy
  • Maple syrup urine disease or family history of disease
  • Allergy to sucralose
  • Currently taking BCAAs

结局指标

主要结局

Recruitment and retention rates

时间窗: 5 weeks

Number enrolled per month, proportion who complete the protocol

Rates of adherence and treatment fidelity

时间窗: 5 weeks

Proportion of subjects consuming full doses

Assessment process and patient acceptability

时间窗: 5 weeks

Proportion of questionnaires properly completed, actiwatches properly worn, and patient acceptance of protocol

次要结局

  • Change in Insomnia Severity Index (ISI)(Baseline; after 3 weeks of intervention)

研究者

申办方类型
Fed
责任方
Principal Investigator
主要研究者

Miranda M Lim

Principal Investigator

Portland VA Medical Center

研究点 (2)

Loading locations...

相似试验